We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+17.84%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.61B
AUM Growth
+$110M
(+4.4%)
Cap. Flow
-$613M
Cap. Flow
% of AUM
-23.5%
Top 10 Holdings %
Top 10 Hldgs %
41.68%
Holding
110
New
10
Increased
19
Reduced
25
Closed
16
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
|
+$48.5M |
| 2 |
Alector
ALEC
|
+$37M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
+$31.6M |
| 4 |
Axogen
AXGN
|
+$30.4M |
| 5 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$27.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$42.3M |
| 2 |
Vericel Corp
VCEL
|
+$37.3M |
| 3 |
eHealth
EHTH
|
+$35.1M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$31.6M |
| 5 |
Universal Health Services
UHS
|
+$28M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 68.74% |
| 2 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HZNP
1
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $171M | 6.55% |
6,462,634
-363,085
| -5% | -$8.6M |
|
2
Q32 Bio
QTTB
$255M
| $145M | 5.56% |
290,391
| – | – |
|
|
ORTX
3
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $143M | 5.5% |
802,360
| – | – |
|
|
PTLA
4
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $90.8M | 3.48% |
2,617,543
+940,129
| +56% | +$27.1M |
|
5
Viatris
VTRS
$20.1B
| $90.7M | 3.48% |
3,199,789
+366,048
| +13% | +$10.7M |
|
|
AERI
6
DELISTED
Aerie Pharmaceuticals
AERI
| $76.4M | 2.93% |
1,608,785
+90,189
| +6% | +$3.97M |
|
|
IMMU
7
DELISTED
Immunomedics Inc
IMMU
| $72.9M | 2.8% |
3,794,783
+1,961,581
| +107% | +$31.6M |
|
|
XENT
8
DELISTED
Intersect ENT, Inc
XENT
| $64.5M | 2.47% |
2,005,964
-72,411
| -3% | -$2.24M |
|
|
XLRN
9
DELISTED
Acceleron Pharma
XLRN
| $58.5M | 2.24% |
1,255,174
-131,367
| -9% | -$5.77M |
|
10
AnaptysBio
ANAB
$1.72B
| $54.3M | 2.08% |
743,439
| – | – |
|
11
BioCryst Pharmaceuticals
BCRX
$2.36B
| $53.2M | 2.04% |
6,537,566
-373,223
| -5% | -$3.2M |
|
|
MYOK
12
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $51.8M | 1.99% |
997,000
| – | – |
|
13
argenx
ARGX
$53.8B
| $49.2M | 1.88% |
393,750
-78,250
| -17% | -$9.2M |
|
14
Sarepta Therapeutics
SRPT
$1.82B
| $46M | 1.76% |
386,000
+44,200
| +13% | +$5.68M |
|
|
DPLO
15
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $41M | 1.57% |
7,049,297
+4,700,304
| +200% | +$48.5M |
|
|
BPMC
16
DELISTED
Blueprint Medicines
BPMC
| $40.6M | 1.56% |
506,865
-14,135
| -3% | -$1.04M |
|
|
17
Axogen
AXGN
$2.12B
| $37.2M | 1.43% |
1,767,006
+1,662,332
| +1,588% | +$30.4M |
|
|
18
Alector
ALEC
$167M
| $36.6M | 1.4% |
+1,956,923
| New | +$37M |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $36.2M | 1.39% |
579,463
-334,810
| -37% | -$15.7M |
|
20
Centene
CNC
$32.8B
| $35.4M | 1.36% |
667,000
+95,000
| +17% | +$5.77M |
|
21
Aclaris Therapeutics
ACRS
$793M
| $35.3M | 1.35% |
5,893,416
| – | – |
|
22
Brookdale Senior Living
BKD
$3.58B
| $34M | 1.3% |
5,161,355
+920,500
| +22% | +$6.76M |
|
|
RARX
23
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $33.6M | 1.29% |
1,502,000
| – | – |
|
|
RETA
24
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $31.1M | 1.19% |
364,000
| – | – |
|
25
Fate Therapeutics
FATE
$324M
| $29.9M | 1.15% |
1,702,897
+48,032
| +3% | +$758K |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q1 2019 Portfolio in Review
As of Q1 2019, Deerfield Management held 110 positions worth $2.61B, up 4.4% from $2.5B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deerfield Management withdrew a net $613M in Q1 2019, closing 16 positions and reducing 25 holdings. Its most notable exit was Allergan plc, an estimated $24.1M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 70% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Alector worth $36.6M.
- Deerfield Management's largest Q1 2019 buy was Alector: 1,956,923 shares worth $36.6M.
- Deerfield Management added most to DIPLOMAT PHARMACY, INC. in Q1 2019, an estimated $48.5M increase.
- Deerfield Management's biggest Q1 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $42.3M.
- Deerfield Management fully exited Allergan plc in Q1 2019, selling an estimated $24.1M.
- Deerfield Management's ten largest holdings make up 42% of its $2.61B portfolio in Q1 2019.
- Deerfield Management opened 10 new positions and closed 16 in Q1 2019.
- Deerfield Management's portfolio value rose 4.4% quarter-over-quarter to $2.61B.
Based on Deerfield Management's 13F filing for Q1 2019, filed 15 May 2019.